Company: SPRB
Filing Date: 2025-04-15
Form Type: S-8
Source: 0000950170-25-054234
Chunk: 0

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-15
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on April 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spruce Biosciences, Inc. (Exact name of registrant as specified in its charter)

| Delaware                                                        |     |                         83-2154263 |
| (State or other jurisdiction ofincorporation or organization)   |     | -I.R.S. EmployerIdentification No. |
| 611 Gateway Boulevard, Suite 740South San Francisco, California |     |                              94080 |
| (Address of Principal Executive Offices)                        |     |                          -Zip Code |

2020 Equity Incentive Plan 2020 Employee Stock Purchase Plan (Full titles of the plans) Javier Szwarcberg, M.D., MPH Chief Executive Officer Spruce Biosciences, Inc. 611 Gateway Boulevard, Suite 740 South San Francisco, California 94080 (415) 655-4168 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to:

| Alexander GefterCooley LLP1333 2nd Street, Suite 400Santa Monica, CA 90401 (310) 883-6400 |

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☒ |     | Smaller reporting company |     | ☒ |
|                         |     |   |     | Emerging growth company   |     | ☒ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>EXPLANATORY NOTE</div>

Pursuant to General Instruction E of Form S-8,